Literature DB >> 23910641

[Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction].

Antonio José Lagoeiro Jorge1, Monica Di Calafiori Freire, Mário Luiz Ribeiro, Luiz Cláudio Maluhy Fernandes, Pedro Gemal Lanzieri, Bruno Afonso Lagoeiro Jorge, João Gabriel B Lage, Maria Luiza Garcia Rosa, Evandro Tinoco Mesquita.   

Abstract

INTRODUCTION: Heart failure with preserved ejection fraction (HFPEF) is a highly prevalent syndrome that is difficult to diagnose in outpatients. The measurement of B-type natriuretic peptide (BNP) may be useful in the diagnosis of HFPEF, but with a different cutoff from that used in the emergency room. The aim of this study was to identify the BNP cutoff for a diagnosis of HFPEF in outpatients. METHODS AND
RESULTS: This prospective, observational study enrolled 161 outpatients (aged 68.1±11.5 years, 72% female) with suspected HFPEF. Patients underwent ECG, tissue Doppler imaging, and plasma BNP measurement, and were classified in accordance with algorithms for the diagnosis of HFPEF. HFPEF was confirmed in 49 patients, who presented higher BNP values (mean 144.4pg/ml, median 113pg/ml, vs. mean 27.6pg/ml, median 16.7pg/ml, p<0.0001). The results showed a significant correlation between BNP levels and left atrial volume index (r=0.554, p<0.0001), age (r=0.452; p<0.0001) and E/E' ratio (r=0.345, p<0.0001). The area under the ROC curve for BNP to detect HFPEF was 0.92 (95% confidence interval: 0.87-0.96; p<0.001), and 51pg/ml was identified as the best cutoff to detect HFPEF, with sensitivity of 86%, specificity of 86% and accuracy of 86%.
CONCLUSIONS: BNP levels in outpatients with HFPEF are significantly higher than in those without. A cutoff value of 51pg/ml had the best diagnostic accuracy in outpatients.
Copyright © 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved.

Entities:  

Keywords:  B-type natriuretic peptide; Diastole; Diástole; Doentes ambulatórios; Heart failure; Insuficiência cardíaca; Outpatients; Peptídeo natriurético tipo B

Mesh:

Substances:

Year:  2013        PMID: 23910641     DOI: 10.1016/j.repc.2012.10.019

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  4 in total

Review 1.  Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group.

Authors:  Sean Collins; Alan B Storrow; Nancy M Albert; Javed Butler; Justin Ezekowitz; G Michael Felker; Gregory J Fermann; Gregg C Fonarow; Michael M Givertz; Brian Hiestand; Judd E Hollander; David E Lanfear; Phillip D Levy; Peter S Pang; W Frank Peacock; Douglas B Sawyer; John R Teerlink; Daniel J Lenihan
Journal:  J Card Fail       Date:  2014-07-18       Impact factor: 5.712

Review 2.  Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group.

Authors:  Sean P Collins; Alan B Storrow; Phillip D Levy; Nancy Albert; Javed Butler; Justin A Ezekowitz; G Michael Felker; Gregory J Fermann; Gregg C Fonarow; Michael M Givertz; Brian Hiestand; Judd E Hollander; David E Lanfear; Peter S Pang; W Frank Peacock; Douglas B Sawyer; John R Teerlink; Daniel J Lenihan
Journal:  Acad Emerg Med       Date:  2014-11-25       Impact factor: 3.451

3.  Metabolomic fingerprint of heart failure with preserved ejection fraction.

Authors:  Beshay N Zordoky; Miranda M Sung; Justin Ezekowitz; Rupasri Mandal; Beomsoo Han; Trent C Bjorndahl; Souhaila Bouatra; Todd Anderson; Gavin Y Oudit; David S Wishart; Jason R B Dyck
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

4.  Effects of fitness qigong and tai chi on middle-aged and elderly patients with type 2 diabetes mellitus.

Authors:  Xiaoyuan Li; Hongyu Si; Yamin Chen; Shouhao Li; Ningning Yin; Zhenlong Wang
Journal:  PLoS One       Date:  2020-12-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.